All episodes
Leveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences Industry
LifeSci Search Podcast: Episode #1
Regenerative Medicine from Humacyte: Off-the-Shelf, Human-Sourced Acellular Vessels for Traumatic Wound Repair
A Brief Chat with Erez Raphael, CEO of DarioHealth
Onconova – Developing Best-in-class Anti-cancer Agents with Multi-faceted MOAs
A Brief Chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc.
A Brief Chat with Martin Welschof, CEO of BioInvent
A Brief Chat with Raphi Levy, CFO of Alpha Tau Medical Ltd.
A Brief Chat with Amir London, CEO of Kamada Ltd.
A Brief Chat with Rob Etherington, President & CEO of Clene, Inc.
Helping the Body Help Itself with EscharEx: The Next Generation Wound-Care Therapeutic from MediWound
A Promising New Immune Checkpoint from Sensei Bio: VISTA
Turning Amino Acids into Drugs: A Novel Platform from Axcella Health
Lipocine Inc’s Formulation for Success: Oral Agents for CNS Disorders
89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset Pegozafermin
De-Risked Oncology Targets with Assets from Checkpoint Therapeutics
Deep Transcranial Magnetic Stimulation (Deep TMS™): BrainsWay’s Innovative and Non-Invasive Therapy for Major Depressive Disorder, Anxious Depression, OCD, and Smoking Addiction
An Oncology Update on CDK 2/9 Inhibition: Cyclacel Pharmaceuticals
Oncology on the Move—Artios: Financing Considerations for an Early Biotech
Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience
Esperion Therapeutics: A Small Company with a Big Heart
Patient-centric, Physician-managed healthcare centers that Payers love: P3 Health Partners
Two Oncology Assets in the Clinic and a sought-after Discovery Platform: Ryvu Therapeutics
Advances in gene therapy delivery: a non-viral pDNA platform that harnesses the power of IL-10
A Pioneer of PARP Inhibition has a New DNA Damage Repair (DDR) Platform
Teclison’s cancer immunotherapy-enhancer, TEC-001, shows efficacy in all-cause hepatic tumors
iBreathe it in: Inhalable drug delivery with the iSPERSE platform, from Pulmatrix
P53 Reactivation via MDM2 Inhibition with Milademetan: Phase 3 Data in 1H 2023 (Rain Therapeutics)
An anti-PD-L1 Antibody Given Subcutaneously: Envafolimab, by Tracon Pharma
Two conditions, one drug: working to relieve chronic cough in IPF, and debilitating itch in prurigo nodularis with the opioid-receptor-targeting drug, HADUVIO
Special Delivery Platforms: pH-activated and STING activating polymeric micelles from OncoNano Medicine
Phase II POC for Immutep’s LAG-3 drug, eftilagimod alpha: ASCO data, and an introduction to CEO Marc Voigt
Inducing Immune Tolerance in Autoimmunity, Gene Therapy, and Beyond: The ImmTOR® Platform, from Selecta Biosciences
Dosing more than Skin Deep: A Transdermal Drug Delivery Platform from Dyve Biosciences
Location, Location, Location: Delivering Your IO Asset Directly to the Lymph Node with Amphiphile
Making sure there’s not a dry eye in the house with Tyrvaya®, from Oyster Point Pharma
The sweet spot (and the market) between the adaptive & innate immune response: Allogeneic Natural Killer T cells (NKT) from Athenex
A Rare (Disease) Opportunity: Amolyt Pharma – Targeting Orphan Diseases of the Endocrine System
A clinical-stage biotech company developing a targeted oral small molecule for synergistic combinations with SOC -that's Cardiff Oncology.
Today’s Oncology Play: Global Reach, Clinical Stage Assets, and a Revenue Stream – Antengene
Dyadic International: Helping to produce biologic vaccines and drugs rapidly, in large quantities and at low cost for a global population.
Differentiated Delivery with DPX® - a Versatile Technology for Immuno-Oncology by IMV Inc.
Developing Drugs for Rare Diseases: Pointers and Pitfalls
Targeting Cancer and Fibrosis. Galecto aims to help patients with their first-in-class, small molecule drugs in clinical development
Mapping Neoantigens in Cancer with Genocea’s ATLAS: What to Include, and What to Avoid in Your Cancer Therapy
Every tumor is a deadly frontier, and to survive it you need a personalized, therapeutic path forward. Enter the AI-centric guidance of Evaxion’s, PIONEER
Water, Water, Everywhere – Innovations in Treating Diuretic-Resistant Fluid Overload: Sequana Medical
Modulation of NMDA Receptors for Pain and CNS Disorders: The Middle Way – that’s Aptinyx
Immatics: Engineering the Right T Cell Receptor for Shared Tumor-Associated Targets
Captor Therapeutics: Top Grades for Degrading Pathologic Proteins in Oncology and Autoimmune Disease: Captor Therapeutics
Discovery Platform for Small Molecule mRNA Drugs like no other: mRNA Lightning, from Anima Biotech
Seeing clearly where the sun don’t shine: A game-changing technology in GI endoscopy from Motus GI
GBS Inc: A Saliva Test for Diabetes Monitoring: An inside look at the Glucose Biosensor Technology
Lean and mean, outsourcing oncology machine: Anixa Biosciences, Inc.
NOXXON: Targeting the Chemokines of the TME to enhance Cancer Therapies
Femasys Inc: Putting the Focus on Women’s Reproductive Health
To Find the best Antigens for Cancer, or COVID, Gritstone bio has the EDGE™
Vincerx Pharma: From Pharmacyclics to Cyclins – The Will and the Way
Repairing Organ Damage – Angion Biomedica
Experience, Passion, and a Plan: Vera Therapeutics, Dr. Marshall Fordyce takes us from the bedside to the boardroom in his mission to treat autoimmune disease
A Promising Repurpose: Tenax Therapeutics Tests the Cancer Drug Imatinib in Pulmonary Arterial Hypertension
Medicenna Therapeutics: Reining in the Fire: Taming IL-2?
Immutep: No Longer Left Behind: LAG-3 Hits the Clinical (Late) Stage
Compugen Pioneering DNAM axis in cancer: TIGIT and PVRIG – Synergistic Checkpoints
HERVs and Nerves: Targeting the viral origins of neurodegenerative disease
Are iNKT cells the next frontier in cancer treatment?
Pixium Vision SA: An Eye Towards the Future: High Tech Treatment for Dry AMD
Arcellx: Plug and Play CAR-T: Modular Immunotherapy
A Time for Cocktails. Polytope: A Potential Treatment for Covid-19
Getting the Bugs out of Alzheimer’s: A New Therapeutic Approach
Switching it Up: Medigene Charts a New Course
Cancer Treatment Goes Viral Featuring: Dr. Matt Coffey, CEO Oncolytics Biotech
BiomX: A Real Phage-Turner
NK cell biology no longer stands for “Not Known”: Michael A. Caligiuri, M.D., Chief Medical Officer, and Co-founder of CytoImmune Therapeutics